Clinical Study
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
Table 5
Live functions at one week and last follow-up.
| | TIPS () | OCT-LAR () | |
| One week | | | | AST (U/L) | 101.8 ± 49.2 | 90.1 ± 40.6 | 0.53 | ALT (U/L) | 104.8 ± 48.1 | 99.6 ± 50.6 | 0.80 | TB (μmol/L) | 53.4 ± 11.2 | 48.6 ± 11.6 | 0.34 | PT (s) | 17.5 ± 1.3 | 17.8 ± 2.1 | 0.63 | Last follow-up | | | | AST (U/L) | 85.8 ± 44.6 | 81.8 ± 41.6 | 0.82 | ALT (U/L) | 91.8 ± 49.5 | 80.3 ± 38.2 | 0.53 | TB (μmol/L) | 45.4 ± 11.7 | 42.1 ± 9.7 | 0.47 | PT (s) | 16.1 ± 1.0 | 17.0 ± 1.7 | 0.13 |
|
|